Asuka licenses thyroid eye disease drug from Minghui for Japan, with $110 million upfront payment
Asuka Pharmaceutical, a subsidiary of Asuka Pharmaceutical Holdings, announced a licensing agreement with Chinese biopharmaceutical company Minghui Pharmaceutical for thyroid eye disease drug candidate MHB018A. Asuka secured exclusive development and sales rights in Japan. The agreement includes a $110 million upfront payment, development- and sales-linked payments, and royalties. The drug candidate is undergoing clinical trials in China and elsewhere.